(Z)-1-(4-pyridyl)-1-propene | 78481-67-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (Z)-1-(4-pyridyl)-1-propene
• 英文别名: -1-(4-Pyridyl)-1-propene；4-[(Z)-prop-1-enyl]pyridine
• CAS: 78481-67-1
• 化学式: C₈H₉N
• 分子量: 119.166
• InChiKey: PWZRAFPNQSAEBD-IHWYPQMZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  -1-Morpholino-1-(4-pyridyl)-1-propene 在 甲醇 、 9-borabicyclo[3.3.1]nonane dimer 作用下， 生成 (Z)-1-(4-pyridyl)-1-propene
  参考文献：
  名称：

  Hydroboration. 86. Convenient conversion of aldehydes and ketones into the corresponding alkenes via hydroboration of their enamines. A remarkably simple synthesis of either (Z)- or (E)-alkenes

  摘要：

  Aldehydes and ketones are converted into the corresponding alkenes via hydroboration of their enamines. Hydroboration of aldehyde enamines by 9-borabicyclo[3.3.1]nonane (9-BBN), followed by methanolysis, affords the corresponding terminal alkenes in 75-90% yields. Unsaturated aldehyde enamines produce the corresponding dienes under these conditions. Enamines derived from substituted cyclic ketones and heterocyclic ketones are readily accommodated in this reaction to afford the corresponding alkenes in very good yields. The synthesis of pure (Z)- or (E)-alkenes is readily achieved from the same acyclic ketone enamine by modification of the hydroboration-elimination procedure: (A) hydroboration by 9-BBN followed by methanolysis or (B) hydroboration by borane methyl sulfide (BMS) followed by methanolysis and hydrogen peroxide oxidation. Mechanistic rationale is provided.

  DOI：

  10.1021/jo00004a038

文献信息

• RING-FUSED HETEROCYCLIC COMPOUND
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20150284384A1

  公开（公告）日：2015-10-08

  The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. [wherein, R 1 represents optionally substituted lower alkyl and the like, R 2 represents optionally substituted lower alkyl and the like, R 3 represents the formula (II): (wherein, n represents 0 or 1, R 3a represents a hydrogen atom and the like, R 3b represents a hydrogen atom and the like, and R 3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W 1 represents a nitrogen atom and the like, W 2 represents a nitrogen atom and the like]

  根据本发明，环融合杂环化合物或其药学上可接受的盐具有T型钙通道调节作用，例如，可用作治疗和/或预防瘙痒的药物。本发明提供了由以下一般式(I)或其药学上可接受的盐等表示的环融合杂环化合物，具有T型钙通道调节作用，可用作治疗和/或预防瘙痒等疾病的治疗和/或预防剂。其中，R1代表可选取代的低碳基等，R2代表可选取代的低碳基等，R3代表公式(II)：（其中，n代表0或1，R3a代表氢原子等，R3b代表氢原子等，R3c代表氢原子等）等，Q代表氢原子等，W1代表氮原子等，W2代表氮原子等。
• Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis
  申请人：Huth Andreas

  公开号：US20110009447A1

  公开（公告）日：2011-01-13

  Substituted benzoic acid amides of formula (I) and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of benzoic acid amides are described.

  本文描述了公式（I）的苯甲酸酰胺替代物及其作为治疗由持续血管生成触发的疾病的药物代理的用途，以及其用于生产苯甲酸酰胺的中间产物。
• Small molecule immunopotentiators and assays for their detection
  申请人：Novartis Vaccines and Diagnostics, Inc.

  公开号：EP2583678A2

  公开（公告）日：2013-04-24

  The invention provides immunostimulatory compositions comprising a small molecule immuno-potentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering SMIP compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. In a further aspect, the invention relates generally to methods of screening for small molecule immuno-modulatory compositions.

  本发明提供了包含小分子免疫促进剂（SMIP）化合物的免疫刺激组合物及其施用方法。还提供了施用有效量的 SMIP 化合物以增强受试者对抗原的免疫应答的方法。本发明还提供了单独施用 SMIP 化合物或与另一种制剂联合施用 SMIP 化合物以治疗癌症、传染性疾病和/或过敏/哮喘的新型组合物和方法。在另一方面，本发明一般涉及筛选小分子免疫调节组合物的方法。
• CONDENSED RING HETEROCYCLIC COMPOUND
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2881394A1

  公开（公告）日：2015-06-10

  The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. [wherein, R1 represents optionally substituted lower alkyl and the like, R2 represents optionally substituted lower alkyl and the like, R3 represents the formula (II): (wherein, n represents 0 or 1, R3a represents a hydrogen atom and the like, R3b represents a hydrogen atom and the like, and R3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W1 represents a nitrogen atom and the like, W2 represents a nitrogen atom and the like]

  根据本发明的环融杂环化合物或其药学上可接受的盐具有 T 型钙通道调节作用，例如可用作治疗和/或预防瘙痒症的药物。本发明提供了由以下通式（I）代表的环融杂环化合物或其药学上可接受的盐等，该化合物具有 T 型钙通道调节作用，可用作治疗和/或预防瘙痒症等的药物。 [其中，R1 代表任选取代的低级烷基等，R2 代表任选取代的低级烷基等，R3 代表式 (II)： (其中，n 代表 0 或 1，R3a 代表氢原子等，R3b 代表氢原子等，R3c 代表氢原子等）等，Q 代表氢原子等，W1 代表氮原子等，W2 代表氮原子等]。
• Convenient conversion of aldehydes and ketones into the corresponding alkenes via hydroboration of their enamines. A remarkably simple synthesis of either (Z)- or (E)-alkenes
  作者：Bakthan Singaram、Christian T. Goralski、Milind V. Rangaishenvi、Herbert C. Brown

  DOI：10.1021/ja00183a068

  日期：1989.1